e-therapeutics produces mixed interims

e-therapeutics, a drug discovery and development company, produced mixed interims with slightly increased losses, but reported progress on its lead cancer drug.

e-therapeutics, a drug discovery and development company, produced mixed interims with slightly increased losses, but reported progress on its lead cancer drug.

As expected, first half losses increased to £1.8m (2011: loss of £1.5m), reflecting increased investment in the business.

The company has cash and liquid resources of £11.7m as of July 31st 2012, (July 31st 2011: £15.3m), following a refinancing in 2011. This is expected to provide sufficient working capital through to mid-2014. As in the same half the previous year, there were no revenues to offset its operating expenses.

During the past six months the AIM-listed biotech has made progress in developing its pipeline of drugs. It's lead cancer drug, ETS2101, has entered US phase I trials with patients with brain cancer, and UK phase 1 trials for patients with solid tumours. The first data is expected by the end of this year, while final results for the brain cancer trial are expected in the fourth quarter of 2013, and for the solid tumour trial in the first quarter of 2014.

Its drug, ETS6103, for patients with major depressive disorder, is also expected to start a phase IIB trial in the second quarter of 2013 with results expected in the second quarter of 2014.

Professor Malcolm Young, Chief Executive Officer of e-Therapeutics, said: "This has been another period of significant progress. In the past six months we have advanced our most important product, the cancer drug ETS2101, into two phase I trials.

"We have also continued to re-shape our drug pipeline, with a clear determination to focus investment into the most promising assets in our discovery and development portfolios. We now look forward to some major clinical milestones and to new outputs from our unique drug discovery platform in network pharmacology."

Invesco, under the direction of Neil Woodford, has a 47.3% stake in the company.

CM

Recommended

Share tips of the week – 19 August
Share tips

Share tips of the week – 19 August

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
19 Aug 2022
How to invest in smart factories as the “fourth industrial revolution” arrives
Share tips

How to invest in smart factories as the “fourth industrial revolution” arrives

Exciting new technologies and trends are coming together to change the face of manufacturing. Matthew Partridge looks at the companies that will drive…
18 Aug 2022
How to invest today? Look to the past, not the future
Investment strategy

How to invest today? Look to the past, not the future

The past few years have seen so many changes to our way of life that many people said we had entered a “new normal”. But as it turns out, the new norm…
18 Aug 2022
A new legal headache for Haleon
Stocks and shares

A new legal headache for Haleon

Haleon, GSK’s former consumer-products arm, spun off last month, has made a dismal debut on the stockmarket.
17 Aug 2022

Most Popular

How to protect your wealth as inflation hits new record highs
Investment strategy

How to protect your wealth as inflation hits new record highs

UK inflation has hit a new record high of 10.1%. It's going to hurt, says Dominic Frisby. Here's how you can protect your wealth.
17 Aug 2022
How to cut your energy bill
Personal finance

How to cut your energy bill

The energy-price cap will almost double in the autumn. What does this mean for your money, and how can you alleviate the squeeze? Ruth Jackson-Kirby h…
17 Aug 2022
Are GSK’s legal troubles a threat to the firm’s survival?
Biotech stocks

Are GSK’s legal troubles a threat to the firm’s survival?

Pharmaceutical giant GlaxoSmithKline is facing legal action over heartburn drug Zantac that has seen billions wiped off its market value. Rupert Hargr…
16 Aug 2022